Anti-double Stranded DNA Antibodies: Origin, Pathogenicity, and Targeted Therapies
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Systemic lupus erythematosus (SLE) is characterized by high-titer serological autoantibodies, including antibodies that bind to double-stranded DNA (dsDNA). The origin, specificity, and pathogenicity of anti-dsDNA antibodies have been studied from a wider perspective. These autoantibodies have been suggested to contribute to multiple end-organ injuries, especially to lupus nephritis, in patients with SLE. Moreover, serum levels of anti-DNA antibodies fluctuate with disease activity in patients with SLE. By directly binding to self-antigens or indirectly forming immune complexes, anti-dsDNA antibodies can accumulate in the glomerular and tubular basement membrane. These autoantibodies can also trigger the complement cascade, penetrate into living cells, modulate gene expression, and even induce profibrotic phenotypes of renal cells. In addition, the expression of suppressor of cytokine signaling 1 is reduced by anti-DNA antibodies simultaneously with upregulation of profibrotic genes. Anti-dsDNA antibodies may even participate in the pathogenesis of SLE by catalyzing hydrolysis of certain DNA molecules or peptides in cells. Recently, anti-dsDNA antibodies have been explored in greater depth as a therapeutic target in the management of SLE. A substantial amount of data indicates that blockade of pathogenic anti-dsDNA antibodies can prevent or even reverse organ damage in murine models of SLE. This review focuses on the recent research advances regarding the origin, specificity, classification, and pathogenicity of anti-dsDNA antibodies and highlights the emerging therapies associated with them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Henault, J., Martinez, J., Riggs, J. M., Tian, J., Mehta, P., Clarke, L., Sasai, M., Latz, E., Brinkmann, M. M., Iwasaki, A., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.09.014 · Cited by 348 · cited 12×
“With the help of IFN-1, autoreactive B cells undergo amplification, somatic mutation of immunoglobulin variable region genes, and class switch recombination, resulting in highaffinity immunoglobulin G (IgG) (20).”
BackgroundInfluentialA surge in anti-dsDNA titer predicts a severe lupus flare within six months
Pan, N., Amigues, I., Lyman, S., Duculan, R., Aziz, F., Crow, M., & Kirou, K. (2014) · Lupus · doi:10.1177/0961203313515763 · Cited by 59 · cited 1×
“Tests for anti-DNA antibodies can be positive at least 2 years before clinical diagnosis of SLE, and a surge in serum levels can present as a predictor for a severe SLE flare-up in the following 6 months (57).”
BackgroundAnti-DNA antibodies cross-react with C1q
Franchin, G., Son, M., Kim, S. J., Ben-Zvi, I., Zhang, J., & Diamond, B. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.06.002 · Cited by 41 · cited 6×
“, ribosomal P proteins (37), C1q (36), annexin II (30), α-actinin (38), and heparan sulfate (35, 46), further confirmed that the antigen-antibody mediation is crucial for the penetration mechanism.”
BackgroundInfluentialCompagno, M., Jacobsen, S., Rekvig, O., Truedsson, L., Heegaard, N., Nossent, J., Jönsen, A., Jacobsen, R., Eilertsen, G., Sturfelt, G., et al. (2013) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2013.765032 · Cited by 34 · cited 1×
“Anti-dsDNA antibodies emerge as a heterogeneous population in SLE, whereas they can be detected in some non-SLE patients with rheumatic symptoms, indicating that the employment of anti-dsDNA antibodies as a criterion for diagnosis and classification without subdivision may result in misdiagnosis and misclassifying of…”
Background
Cited by
Glycosylation: mechanisms, biological functions and clinical implications
He, M., Zhou, X., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01886-1 · Cited by 499
Self-citationRekvig, O. P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.569234 · Cited by 42
Comparison of current methods for anti‐dsDNA antibody detection and reshaping diagnostic strategies
Infantino, M., Palterer, B., Previtali, G., Alessio, M., Villalta, D., Carbone, T., Platzgummer, S., Paura, G., Castiglione, C., Fabris, M., et al. (2022) · Scandinavian Journal of Immunology · doi:10.1111/sji.13220 · Cited by 20
Trujillo Aguilera, A., Bernardo Serrano, R., Navas, A., Alcaide Molina, J., Alvarez Romero, P., & Jurado Roger, A. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2023-000984 · Cited by 6
Metadata
- Authors
- Wang, X., & Xia, Y.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-07-17
- Volume
- 10
- Pages
- 1667-1667
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2962616530
- Cited by
- 182
- References
- 4
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-double Stranded DNA Antibodies: Origin, Pathogenicity, and Targeted Therapies. https://app.cochat.ai/papers/10.3389/fimmu.2019.01667
- The paper
- Wang, X., & Xia, Y. (2019). Anti-double Stranded DNA Antibodies: Origin, Pathogenicity, and Targeted Therapies. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2019.01667
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.